Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy

Next Previous
Search
Trial Profile

A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vofatamab (Primary) ; Docetaxel
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms FIERCE-21
  • Sponsors Rainier Therapeutics

    • Most Recent Events

    • 14 Nov 2019 Status changed from active, no longer recruiting to discontinued.
    • 04 Jun 2019 Results from P2 (n=21) were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 25 Apr 2019 According to a Rainier Therapeutics media release,interim analysis data from phase 2 part of this study will be presented at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting, which will take place May 31 to June 4, 2019 in Chicago, Illinois.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top